{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:00:40Z","timestamp":1792512040955,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s11908-006-0012-x","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:51:10Z","timestamp":1180061470000},"page":"162-170","source":"Crossref","is-referenced-by-count":32,"title":["Osteopenia and osteoporosis in patients with HIV: A review of current concepts"],"prefix":"10.1007","volume":"8","author":[{"given":"Todd T.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A.","family":"McComsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-200003100-00005","volume":"14","author":"P Tebas","year":"2000","unstructured":"Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63-F67.","journal-title":"AIDS"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00002030-200104130-00005","volume":"15","author":"A Carr","year":"2001","unstructured":"Carr A, Miller J, Eisman JA, Cooper DA: Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001, 15:703\u2013709.","journal-title":"AIDS"},{"key":"12_CR3","doi-asserted-by":"crossref","unstructured":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94:646\u2013650.","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"12_CR4","first-page":"1","volume":"843","author":"World Health Organization","year":"1994","unstructured":"World Health Organization: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of WHO study group. World Health Org Tech Rep Ser 1994, 843:1\u2013129.","journal-title":"World Health Org Tech Rep Ser"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254\u20131259.","journal-title":"BMJ"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/B978-012098652-1\/50193-1","volume-title":"Principles of Bone Biology.","author":"GM Blake","year":"2002","unstructured":"Blake GM, Fogelman I: Methods and clinical issues in bone densitometry and quantitative ultrasonography. In Principles of Bone Biology. Edited by Bilezikian JP, Raisz LG, Rodan GA. San Diego: Academic Press; 2002: 1573\u20131585."},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","volume":"34","author":"SC Schuit","year":"2004","unstructured":"Schuit SC, van der KM, Weel AE, et al.: Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 2004, 34:195\u2013202.","journal-title":"Bone"},{"key":"12_CR8","unstructured":"Brown TT, Qaqish R: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analysis [abstract 87]. Paper presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13\u201316, 2005."},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/367569","volume":"36","author":"K Mondy","year":"2003","unstructured":"Mondy K, Yarasheski K, Powderly WG, et al.: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003, 36:482\u2013490. One of the first longitudinal studies of BMD in patients with HIV infection. Also, one of the only studies to have bone biopsy data.","journal-title":"Clin Infect Dis"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","volume":"17","author":"PW Mallon","year":"2003","unstructured":"Mallon PW, Miller J, Cooper DA, Carr A: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003, 17:971\u2013979.","journal-title":"AIDS"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1310\/4X0H-UVMJ-BHYW-CPFB","volume":"4","author":"J Fernandez-Rivera","year":"2003","unstructured":"Fernandez-Rivera J, Garcia R, Lozano F, et al.: Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003, 4:337\u2013346.","journal-title":"HIV Clin Trials"},{"key":"12_CR12","unstructured":"Powderly WG, Cohen C, Gallant JE, et al.: Similar incidence of osteopenia and osteoporosis in ART-naive patients treated with tenofovir DF or stavudine in combination with lamivudine or efavirenz over 144 weeks [abstract 823]. Presented at the 12th Conference of Retroviruses and Opportunistic Infections. Boston, MA; February 22\u201325, 2005."},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1210\/jc.2003-031506","volume":"89","author":"TT Brown","year":"2004","unstructured":"Brown TT, Ruppe MD, Kassner R, et al.: Reduced bone mineral density in human immunodeficiency virusinfected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004, 89:1200\u20131206.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR14","first-page":"145","volume":"84","author":"P Aukrust","year":"1999","unstructured":"Aukrust P, Haug CJ, Ueland T, et al.: Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999, 84:145\u2013150.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/01.aids.0000176231.24652.02","volume":"19","author":"M Konishi","year":"2005","unstructured":"Konishi M, Takahashi K, Yoshimoto E, et al.: Association between osteopenia\/osteoporosis and the serum RANKL in HIV-infected patients. AIDS 2005, 19:1240\u20131241.","journal-title":"AIDS"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1468-1293.2005.00278.x","volume":"6","author":"E Seminari","year":"2005","unstructured":"Seminari E, Castagna A, Soldarini A, et al.: Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005, 6:145\u2013150.","journal-title":"HIV Med"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1258\/09564620260216362","volume":"13","author":"SF Forsyth","year":"2002","unstructured":"Forsyth SF, Gazzard BG, Nelson MR: A case of march fracture in a patient with osteoporosis on long-term HAART. Int J STD AIDS 2002, 13:645\u2013646.","journal-title":"Int J STD AIDS"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00002030-200101050-00025","volume":"15","author":"G Guaraldi","year":"2001","unstructured":"Guaraldi G, Ventura P, Albuzza M, et al.: Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 2001, 15:137\u2013138.","journal-title":"AIDS"},{"key":"12_CR19","first-page":"496","volume":"20","author":"JA Nuevo","year":"2003","unstructured":"Nuevo JA, Moreno F, Gonzalez-Castillo J, et al.: Pathologic fracture of the sacrum in an HIV patient treated with highly active antiretroviral therapy. An Med Internal 2003, 20:496\u2013497.","journal-title":"An Med Internal"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/154510970400300303","volume":"3","author":"GA McComsey","year":"2004","unstructured":"McComsey GA, Huang JS, Woolley IJ, et al.: Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic Ill) 2004, 3:86\u201391.","journal-title":"J Int Assoc Physicians AIDS Care (Chic Ill)"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00002030-200105250-00005","volume":"15","author":"JS Huang","year":"2001","unstructured":"Huang JS, Rietschel P, Hadigan CM, et al.: Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001, 15:975\u2013982.","journal-title":"AIDS"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1359\/JBMR.0301246","volume":"19","author":"C Amiel","year":"2004","unstructured":"Amiel C, Ostertag A, Slama L, et al.: BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004, 19:402\u2013409.","journal-title":"J Bone Miner Res"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1172\/JCI15797","volume":"114","author":"MW Wang","year":"2004","unstructured":"Wang MW, Wei S, Faccio R, et al.: The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004, 114:206\u2013213.","journal-title":"J Clin Invest"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"48251","DOI":"10.1074\/jbc.M304676200","volume":"278","author":"JM Fakruddin","year":"2003","unstructured":"Fakruddin JM, Laurence J: HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma\/RANKL cross-talk. J Biol Chem 2003, 278:48251\u201348258.","journal-title":"J Biol Chem"},{"key":"12_CR25","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/00002030-200107060-00009","volume":"15","author":"D Nolan","year":"2001","unstructured":"Nolan D, Upton R, McKinnon E, et al.: Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001, 15:1275\u20131280.","journal-title":"AIDS"},{"key":"12_CR26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00126334-200205010-00020","volume":"30","author":"J Gold","year":"2002","unstructured":"Gold J, Pocock N, Li Y: Bone mineral density abnormalities in patients with HIV infection. J Acquir Immune Defic Syndr 2002, 30:131\u2013132.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","volume":"14","author":"SA Mallal","year":"2000","unstructured":"Mallal SA, John M, Moore CB, et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309\u20131316.","journal-title":"AIDS"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","volume":"18","author":"A Martin","year":"2004","unstructured":"Martin A, Smith DE, Carr A, et al.: Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004, 18:1029\u20131036.","journal-title":"AIDS"},{"key":"12_CR29","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1089\/0889222041217482","volume":"20","author":"G Pan","year":"2004","unstructured":"Pan G, Wu X, McKenna MA, et al.: AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses 2004, 20:608\u2013620.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","volume":"38","author":"GA McComsey","year":"2004","unstructured":"McComsey GA, Ward DJ, Hessenthaler SM, et al.: Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004, 38:263\u2013270.","journal-title":"Clin Infect Dis"},{"key":"12_CR31","first-page":"F204","volume":"245","author":"DA Bushinsky","year":"1983","unstructured":"Bushinsky DA, Krieger NS, Geisser DI, et al.: Effects of pH on bone calcium and proton fluxes in vitro. Am J Physiol 1983, 245:F204-F209.","journal-title":"Am J Physiol"},{"key":"12_CR32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"JE Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191\u2013201. Landmark randomized trial proving the detrimental effects of stavudine on fat wasting and the modest, but significant risk of bone loss with tenofovir.","journal-title":"JAMA"},{"key":"12_CR33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1359\/jbmr.2004.19.5.714","volume":"19","author":"KE Earle","year":"2004","unstructured":"Earle KE, Seneviratne T, Shaker J, Shoback D: Fanconi\u2019s syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004, 19:714\u2013721.","journal-title":"J Bone Miner Res"},{"key":"12_CR34","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0736-0266(02)00074-8","volume":"20","author":"AB Castillo","year":"2002","unstructured":"Castillo AB, Tarantal AF, Watnik MR, Martin RB: Tenofovir treatment at 30 mg\/kg\/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J Orthop Res 2002, 20:1185\u20131189.","journal-title":"J Orthop Res"},{"key":"12_CR35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s002239900288","volume":"61","author":"NI Paton","year":"1997","unstructured":"Paton NI, Macallan DC, Griffin GE, Pazianas M: Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997, 61:30\u201332.","journal-title":"Calcif Tissue Int"},{"key":"12_CR36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00002030-200101260-00022","volume":"15","author":"A Lawal","year":"2001","unstructured":"Lawal A, Engelson ES, Wang J, et al.: Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 2001, 15:278\u2013280.","journal-title":"AIDS"},{"key":"12_CR37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2003.10.005","volume":"15","author":"TS Kwan","year":"2004","unstructured":"Kwan TS, Padrines M, Theoleyre S, et al.: IL-6, RANKL, TNF-alpha\/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004, 15:49\u201360.","journal-title":"Cytokine Growth Factor Rev"},{"key":"12_CR38","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1210\/jcem.83.11.5270","volume":"83","author":"CJ Haug","year":"1998","unstructured":"Haug CJ, Aukrust P, Haug E, et al.: Severe Deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998, 83:3832\u20133838.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00705-004-0395-7","volume":"150","author":"JM Fakruddin","year":"2005","unstructured":"Fakruddin JM, Laurence J: HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005, 150:67\u201378.","journal-title":"Arch Virol"},{"key":"12_CR40","first-page":"39","volume":"48","author":"G Madeddu","year":"2004","unstructured":"Madeddu G, Spanu A, Solinas P, et al.: Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004, 48:39\u201348.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"12_CR41","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/00002030-200309050-00010","volume":"17","author":"D Bruera","year":"2003","unstructured":"Bruera D, Luna N, David DO, et al.: Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003, 17:1917\u20131923.","journal-title":"AIDS"},{"key":"12_CR42","first-page":"623","volume-title":"Principles and Practice of Endocrinology and Metabolism.","author":"R Lindsay","year":"2005","unstructured":"Lindsay R, Cosman F: Osteoporosis. In Principles and Practice of Endocrinology and Metabolism. Edited by Becker KL. Philadelphia: Lippincott Williams & Wilkins; 2005:623\u2013642."},{"key":"12_CR43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002030-200402200-00014","volume":"18","author":"SE Dolan","year":"2004","unstructured":"Dolan SE, Huang JS, Killilea KM, et al.: Reduced bone density in HIV-infected women. AIDS 2004, 18:475\u2013483.","journal-title":"AIDS"},{"key":"12_CR44","doi-asserted-by":"crossref","unstructured":"Yin M, Dobkin J, Brudney K, et al.: Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005, 1345\u20131352.","DOI":"10.1007\/s00198-005-1845-0"},{"key":"12_CR45","first-page":"4108","volume":"81","author":"AS Dobs","year":"1996","unstructured":"Dobs AS, Few WL III, Blackman MR, et al.: Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab 1996, 81:4108\u20134112.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR46","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1210\/jcem.86.8.7728","volume":"86","author":"JS Huang","year":"2001","unstructured":"Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S: Reduced bone density in androgen-Deficient women with acquired immune Deficiency syndrome wasting. J Clin Endocrinol Metab 2001, 86:3533\u20133539.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00774-004-0541-z","volume":"23","author":"L Rosenthall","year":"2005","unstructured":"Rosenthall L, Falutz J: Bone mineral and soft-tissue changes in AIDS-associated lipoatrophy. J Bone Miner Metab 2005, 23:53\u201357.","journal-title":"J Bone Miner Metab"},{"key":"12_CR48","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1210\/jc.2004-1466","volume":"90","author":"P Koutkia","year":"2005","unstructured":"Koutkia P, Canavan B, Breu J, Grinspoon S: Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J Clin Endocrinol Metab 2005, 90:2154\u20132160.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR49","doi-asserted-by":"crossref","unstructured":"Samaras K, Pett S, Gowers A, et al.: Iatrogenic Cushing\u2019s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005, 4394\u20134398.","DOI":"10.1210\/jc.2005-0036"},{"key":"12_CR50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00126334-200211010-00001","volume":"31","author":"M Schambelan","year":"2002","unstructured":"Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257\u2013275.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"12_CR51","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/jbmr.040211","volume":"19","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Black DM, et al.: Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004, 19:764\u2013772.","journal-title":"J Bone Miner Res"},{"key":"12_CR52","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00198-004-1709-z","volume":"16","author":"K Siminoski","year":"2005","unstructured":"Siminoski K, Jiang G, Adachi JD, et al.: Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int 2005, 16:403\u2013410.","journal-title":"Osteoporos Int"},{"key":"12_CR53","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1359\/jbmr.2003.18.10.1789","volume":"18","author":"P Garnero","year":"2003","unstructured":"Garnero P, Mulleman D, Munoz F, et al.: Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 2003, 18:1789\u20131794.","journal-title":"J Bone Miner Res"},{"key":"12_CR54","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1359\/jbmr.1999.14.4.602","volume":"14","author":"Castro MA Braga de","year":"1999","unstructured":"Braga de Castro MA, Hannon R, Eastell R: Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999, 14:602\u2013608.","journal-title":"J Bone Miner Res"},{"key":"12_CR55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7326\/0003-4819-123-6-199509150-00010","volume":"123","author":"N Kelepouris","year":"1995","unstructured":"Kelepouris N, Harper KD, Gannon F, et al.: Severe osteoporosis in men. Ann Intern Med 1995, 123:452\u2013460.","journal-title":"Ann Intern Med"},{"key":"12_CR56","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2002-020275","volume":"87","author":"C Tannenbaum","year":"2002","unstructured":"Tannenbaum C, Clark J, Schwartzman K, et al.: Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002, 87:4431\u20134437.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-129-2-199807150-00002","volume":"129","author":"EW Gregg","year":"1998","unstructured":"Gregg EW, Cauley JA, Seeley DG, et al.: Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998, 129:81\u201388.","journal-title":"Ann Intern Med"},{"key":"12_CR58","unstructured":"Rosen HN, Drezner MK: Overview of the management of osteoporosis in women. In UpToDate. Edited by Rose BD. Wellsley, MA; 2005. Available at http:\/\/www. patients.uptodate.com\/topic.asp?.le=minmetab\/ 13865&title=Celiac+disease."},{"key":"12_CR59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.qai.0000145352.04440.1e","volume":"38","author":"K Mondy","year":"2005","unstructured":"Mondy K, Powderly WG, Claxton SA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia\/ osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005, 38:426\u2013431. Pilot study in patients with HIV infection showing improvements in BMD with alendronate with good tolerability.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"12_CR60","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","volume":"19","author":"KE Ensrud","year":"2004","unstructured":"Ensrud KE, Barrett-Connor EL, Schwartz A, et al.: Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004, 19:1259\u20131269.","journal-title":"J Bone Miner Res"},{"key":"12_CR61","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, et al.: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294\u20131301.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR62","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, et al.: Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189\u20131199.","journal-title":"N Engl J Med"},{"key":"12_CR63","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2005-0057","volume":"90","author":"SM Ott","year":"2005","unstructured":"Ott SM: Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005, 90:1897\u20131899. Well-written editorial which explores some of the concerns of long term bisphosphonate therapy.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR64","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216\u20131226.","journal-title":"N Engl J Med"},{"key":"12_CR65","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","volume":"353","author":"F Cosman","year":"2005","unstructured":"Cosman F, Nieves J, Zion M, et al.: Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566\u2013575.","journal-title":"N Engl J Med"},{"key":"12_CR66","first-page":"504","volume":"86","author":"P Rietschel","year":"2001","unstructured":"Rietschel P, Hadigan C, Corcoran C, et al.: Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001, 86:504\u2013510.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-006-0012-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-006-0012-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-006-0012-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:22:03Z","timestamp":1559434923000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-006-0012-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s11908-006-0012-x","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}